1. CDK4/6 inhibitors for hormone receptor-positive/human epidermal growth factor receptor 2 negative advanced breast cancer: A rapid health technology assessment
   Hangye Gu et al, 2023, Medicine CrossRef
2. Research Progress in the Related Mechanisms of Cyclin-Dependent Kinase 4 and 6 Inhibitors in the Treatment of Breast Cancer
   ·别克拉米斯 乌尔肯, 2023, Advances in Clinical Medicine CrossRef
3. Identification of a Panel of miRNAs Associated with Resistance to Palbociclib and Endocrine Therapy
   Rosalba Torrisi et al, 2024, International Journal of Molecular Sciences CrossRef
4. CD63+ cancer-associated fibroblasts confer CDK4/6 inhibitor resistance to breast cancer cells by exosomal miR-20
   Jiahui Sun et al, 2024, Cancer Letters CrossRef
5. The Expression of Cell Cycle-Related Genes in USP8-Mutated Corticotroph Neuroendocrine Pituitary Tumors and Their Possible Role in Cell Cycle-Targeting Treatment
   Beata Joanna Mossakowska et al, 2022, Cancers CrossRef
6. MYCN Amplification, along with Wild-Type RB1 Expression, Enhances CDK4/6 Inhibitors’ Efficacy in Neuroblastoma Cells
   Piergiuseppe De Rosa et al, 2023, International Journal of Molecular Sciences CrossRef
7. A retrospective study on the mechanism underlying quick transfer from response to resistance in a repeated recurrent chordoma patient with molecular alterations treated with Palbociclib
   Nanzhe Zhong et al, 2024, Journal of Cancer Research and Clinical Oncology CrossRef
8. Capivasertib in Hormone Receptor–Positive Advanced Breast Cancer
   Nicholas C. Turner et al, 2023, New England Journal of Medicine CrossRef
9. Efficacy of CDK4/6 inhibitors combined with endocrine therapy in HR+/HER2− breast cancer: an umbrella review
   Dongqing Pu et al, 2024, Journal of Cancer Research and Clinical Oncology CrossRef
10. The effects of Abemaciclib on cell cycle and apoptosis regulation in anaplastic thyroid cancer cells
    Elaheh S. Abutorabi et al, 2023, Molecular Biology Reports CrossRef
11. The value of oral selective estrogen receptor degraders in patients with HR-positive, HER2-negative advanced breast cancer after progression on ≥ 1 line of endocrine therapy: systematic review and meta-analysis
    Xiewei Huang et al, 2024, BMC Cancer CrossRef
12. Progression after First-Line Cyclin-Dependent Kinase 4/6 Inhibitor Treatment: Analysis of Molecular Mechanisms and Clinical Data
    Federica Villa et al, 2023, International Journal of Molecular Sciences CrossRef
13. Prognostic Parameters of Palbociclib in HR+/HER2- Advanced Breast Cancer: A Narrative Review
    Wei Wang et al, 2023, Technology in Cancer Research & Treatment CrossRef
14. Design, synthesis, and antitumor activity of benzimidazole derivatives as CDK4/6 inhibitors
    Xiu-Jun Wang et al, 2024, Journal of Molecular Structure CrossRef
15. Mechanisms of Resistance to CDK4/6 Inhibitors and Predictive Biomarkers of Response in HR+/HER2-Metastatic Breast Cancer—A Review of the Literature
    Ioana-Miruna Stanciu et al, 2023, Diagnostics CrossRef